

Cancer Epidemiology Biomarkers & Prevention

June 1995
Volume Four ■ Number Four
Pages 301-436
ISSN 1055-9965



An Official Journal of the
American Association for Cancer Research
Cosponsored by the
American Society of Preventive Oncology



AMERICAN ASSOCIATION FOR CANCER RESEARCH SCIENTIFIC CONFERENCES

OCTOBER 14-18, 1995

Cytokines and Cytokine Receptors

Chairperson: Steven Gillis, Seattle, WA
The Sagamore, Bolton Landing (Lake George), NY

NOVEMBER 5-9, 1995

Cancer: The Interface Between Basic and Applied Research

Chairpersons: Bert Vogelstein, Baltimore, MD;
Stephen H. Friend, Seattle, WA; John D. Minna, Dallas, TX
Stouffer Harborplace Hotel, Baltimore, MD

NOVEMBER 17-21, 1995

Novel Strategies Against Resistant Cancers

Chairpersons: Victor Ling, Toronto, Ontario, Canada; Daniel D. Von Hoff, San Antonio, TX
Sanibel Harbour Resort & Spa, Ft. Myers, FL

DECEMBER 2-6, 1995

The Molecular Basis of Gene Transcription

Chairperson: Tom Curran, Nutley, NJ
Hotel Del Coronado, San Diego, CA

JANUARY 17-20, 1996

Cancer and the Cell Cycle

Joint Meeting with the Swiss Institute for Experimental Cancer Research
Chairpersons: Edward E. Harlow, Charlestown, MA; Viesturs Simanis, Lausanne, Switzerland
Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland

FEBRUARY 19-25, 1996

Cancer Susceptibility Genes and Molecular Carcinogenesis

Chairpersons: Curtis C. Harris, Bethesda, MD; Allan Balmain, Glasgow, Scotland; Kenneth Olden, Research Triangle Park, NC
Keystone Resort, Keystone, CO

MARCH 1-5, 1996

Proteases and Their Inhibitors in Cancer

Chairpersons: Lynn M. Matrisian, Nashville, TN; Bonnie F. Sloane, Detroit, MI
Marriott's Bay Point Resort, Panama City Beach, FL

APRIL 20-24, 1996

87th Annual Meeting

Chairperson: Lorraine J. Gudas, New York, NY
Washington D.C. Convention Center, Washington, D.C.

Abstract Deadline: December 1, 1995

JUNE 8-12, 1996

Inducible Genomic Responses

Chairpersons: William T. Beck, Memphis, TN; John A. Hickman, Birmingham, England; Richard I. Morimoto, Evanston, IL
Skamania Lodge, Stevenson (Columbia River Gorge), WA

OCTOBER 2-6, 1996

Novel Approaches in Blood and Marrow Transplantation

Second Annual Meeting of the American Society for Blood and Marrow Transplantation
Chairpersons: O. Michael Colvin, Baltimore, MD; Bruce R. Blazar, Minneapolis, MN
Hotel Del Coronado, San Diego, CA

OCTOBER 6-9, 1996

Carcinogenesis from Environmental Pollution: Assessment of Human Risks and Strategies for Prevention

Joint Meeting with International Agency for Research on Cancer
Chairpersons: Frederica Perera, New York, NY; Paul Kleihues, Lyon, France
Hotel Gellért, Budapest, Hungary

OCTOBER 19-23, 1996

Programmed Cell Death

Chairperson: Stanley J. Korsmeyer, St. Louis, MO
The Sagamore, Bolton Landing (Lake George), NY

NOVEMBER 16-20, 1996

Disrupted Transcription Factors in Cancer

Chairpersons: Peter K. Vogt, La Jolla, CA; Frank J. Rauscher III, Philadelphia, PA
Hotel Del Coronado, San Diego, CA

AACR members will receive brochures on the above special conferences as soon as they are available. Nonmembers should call or write:

American Association for Cancer Research
Public Ledger Building, Suite 816
150 South Independence Mall West
Philadelphia, PA 19106-3483
215-440-9300 • 215-440-9313 (FAX)

Cancer Epidemiology & Prevention

An Official Journal of the American Association for Cancer Research ■ Cosponsored by the American Society of Preventive Oncology

American Association for Cancer Research, Inc.

**Executive Director and
Director of Publications**
Margaret Foti

Publications Staff Associate Director of Publications

Mary Anne Mennite
Manager, Editorial Services

Heide M. Pusztay
Staff Editors

Lisa A. Chippendale
Pamela M. Grebow
Michael J. Beveridge
Kathleen C. Assenmacher
Pamela R. Arnold

Supervisor, Manuscript Processing
Margaret A. Pickels

**Assistant Supervisor, Manuscript
Processing**

Theresa A. Griffith

Staff Assistant

Mary Ellen Pirring

Editorial Assistants

Valerie L. Taylor
Andrea Conrad
Katherine V. Pawlowski
Bethann Massarella
Charles W. Wells, Jr.

Administrative Staff

Director of Administration

Adam D. Blistein

Controller

Joan D. Brokenshire

Coordinator, Financial Operations

George L. Moore

Meetings Coordinator

Jeffrey M. Ruben

Meeting Planner

Carole L. Kanoff

Public Information Coordinator

Jenny Anne Horst-Martz

Executive Assistant for Programs

Ruth E. Fortson

Administrative Assistant

Robin E. Felder

Systems Specialist

Lydia I. Rodriguez

Staff Assistant

Lori L. Holmes

Secretary

Malika L. Wright

Editorial Secretary

Diana F. Certo

Office Clerk

James J. Waters

Data Entry Clerk

Robert A. Simms II

Office of the Editor-in-Chief

Editorial Secretary

Cheryl C. Carter

Editor-in-Chief

Pelayo Correa

Associate Editors

W. Robert Bruce

Webster K. Cavenue

Joseph F. Fraumeni, Jr.

Ellen R. Gritz

Curtis C. Harris

Stephen S. Hecht

Barbara S. Hulka

Fred F. Kadlubar

Laurence N. Kolonel

Frederick P. Li

W. Thomas London

Thomas E. Moon

Abraham M. Y. Nomura

John D. Potter

James A. Swenberg

Steven R. Tannenbaum

Alice S. Whittemore

Chung S. Yang

Mimi C. Yu

Assistant Editor

Elizabeth T. H. Fontham

Editorial Advisory Board

David B. Abrams

Hans-Olov Adami

Bruce K. Armstrong

Helmut Bartsch

Valerie Beral

John S. Bertram

Joan R. Bloom

William J. Blot

John D. Boice, Jr.

George E. Bonney

Ricardo R. Brentani

Eva Buiatti

Neil E. Caporaso

Lan Bo Chen

Philip Cole

K. Michael Cummings

Susan J. Curry

Eduardo DeStefani

Paul F. Engstrom

Virginia L. Ernster

Yu Tang Gao

E. Robert Greenberg

Raymond S. Greenberg

Peter Greenwald

John D. Groopman

F. Peter Guengerich

Clark W. Heath, Jr.

Kari Hemminki

Rolando Herrero

Elizabeth A. Holly

Lars-Erik Holm

Waun Ki Hong

Robert N. Hoover

Geoffrey R. Howe

Ronald H. Jensen

Mary Claire King

Leo J. Kinlen

Paul Kleihues

Alfred G. Knudson, Jr.

Lance A. Liotta

Martin Lipkin

Richard R. Love

Thomas Mack

Frank L. Meyskens, Jr.

Christopher J. Michejda

Rodney F. Minchin

John D. Minna

Ruggero Montesano

John J. Mulvihill

Nubia Muñoz

Alfred I. Neugut

Gilbert S. Omenn

C. Tracy Orleans

David L. Page

Frederica Perera

Nicholas L. Petrakis

John P. Pierce

Miriam C. Poirier

Bruce A. J. Ponder

Ross Prentice

Barbara Rimer

George C. Roush

Jose Russo

Jonathan M. Samet

Rodolfo Saracci

Mark H. Schiffman

David Schottenfeld

Paul A. Schulte

Roy E. Shore

Margaret R. Spitz

Louise C. Strong

Takashi Sugimura

G. Marie Swanson

Cesar Victora

Jürgen Wahrendorf

Nicholas Wald

Lee W. Wattenberg

I. Bernard Weinstein

John H. Weisburger

Noel S. Weiss

Ainsley Weston

Walter C. Willett

Rodger J. Winn

Gerald N. Wogan

Sandra R. Wolman

Ernst L. Wynder

Witold Zatonski

Harald zur Hausen

Cancer Epidemiology, Biomarkers & Prevention is published eight times a year, one volume annually, by the American Association for Cancer Research, Inc. Except for members of the American Association for Cancer Research, all subscriptions are payable in advance to *Cancer Epidemiology, Biomarkers & Prevention*, P. O. Box 3000, Denville, NJ 07834 [Telephone: (800) 875-2997; FAX: (201) 627-5872], to which all business communications, remittances (in United States currency or its equivalent), and subscription orders should be sent. In Japan, send orders and inquiries to (sole agent): USACO Corporation, Tsutsumi Bldg., 13-12, Shimbashi 1-chome, Minato-ku, Tokyo 105, Japan; Tel. (03) 502-6471. Nonmembers of the American Association for Cancer Research within the United States may subscribe to Volume 4 (1995) of *Cancer Epidemiology, Biomarkers & Prevention* at the rate of \$85 (individual nonmembers) or \$165 (institutional nonmembers), including postage. Institutional and individual nonmembers outside of the United States should add \$20 to their respective rates to offset second-class postage costs. Canadian subscribers should add 7% GST. Changes of address notification should be sent 60 days in advance and include both old and new addresses. Member subscribers should send address changes to: Member Services, American Association for Cancer Research, Inc., Public Ledger Bldg., Suite 816, 150 South Independence Mall West, Philadelphia, PA 19106-3483. Nonmember subscribers should send changes of address to: *Cancer Epidemiology, Biomarkers & Prevention*, P. O. Box 3000, Denville, NJ 07834. Copies of the journal which are undeliverable because of address changes will be destroyed. Accelerated mailing of journals to AACR members in Japan is supported by a generous grant from the Banyu Pharmaceutical Company.



Notice to Members of the American Association for Cancer Research

Officers for 1995–1996

President: Joseph R. Bertino, Memorial Sloan-Kettering Cancer Center, New York, NY 10021

President-Elect: Louise C. Strong, UT M. D. Anderson Cancer Center, Houston, TX 77030

Treasurer: Bayard D. Clarkson, Memorial Sloan-Kettering Cancer Center, New York, NY 10021

Executive Director: Margaret Foti, AACR, Public Ledger Bldg., Suite 816, Philadelphia, PA 19106-3483

Annual Dues

The annual dues of active members of the American Association for Cancer Research are \$160, \$50 of which may be applied toward a subscription to *Cancer Epidemiology, Biomarkers & Prevention*. Corresponding members of the Association will be charged an appropriate fee to offset second-class postage costs. Payment of dues and changes of address of members of the Association should be sent promptly to Margaret Foti, Executive Director, American Association for Cancer Research, Public Ledger Bldg., Suite 816, 150 South Independence Mall West, Philadelphia, PA 19106-3483; Telephone: (215)440-9300; FAX: (215)440-9313.

Submission of Manuscripts

Cancer Epidemiology, Biomarkers & Prevention publishes original research on cancer causation and prevention in humans, linking three previously unintegrated disciplines: epidemiology, biomarkers, and prevention. Topics include descriptive, analytical, biochemical, and molecular epidemiology; the use of biomarkers to study the neoplastic and preneoplastic processes in humans; chemoprevention and other types of prevention trials; and the role of behavioral factors in cancer etiology and prevention. Manuscripts that address individual subjects in any of the three disciplines are welcome as well as manuscripts with an interdisciplinary approach. All submissions undergo peer review. Papers should be sent directly to Pelayo Correa, M. D., Editor-in-Chief, CEBP, Dept. of Pathology, Louisiana State University Medical Center, 1901 Perdido Street, New Orleans, LA 70112-1393. See Instructions for Authors (page i of this issue) for further information concerning submissions.

Back Issues and Single Copy Sales of the Journal

Copies of back stock of the journal may be ordered from *Cancer Epidemiology, Biomarkers & Prevention*, P. O. Box 3000, Denville, NJ 07834 [Telephone: (800) 875-2997; FAX: (201) 627-5872]. As long as supplies permit, single copies will be sold by this company at \$12.50/copy. Orders outside the U.S. add \$1.50/copy to offset postage costs.

Advertisements

Advertisement insertion orders and copy must be received five weeks prior to the date of issue in which the advertisement is to be published. The journal is mailed on approximately the 10th day of the month of issue. Inquiries about advertising should be directed to: M. J. Mrvica Associates, Inc., 155 South White Horse Pike, Berlin, NJ 08009 [Telephone: (609) 768-9360; FAX: (609) 753-0064].

Copyright and Permissions

Authors who wish to publish in *Cancer Epidemiology, Biomarkers & Prevention* must formally transfer copyright to the proprietor of the journal, the American Association for Cancer Research, Inc. It is understood by this transfer that the authors relinquish all exclusive rights of copyright ownership, including the rights of reproduction, derivation, distribution, sale, and display.

Authors who prepared their articles as part of their official duties as employees of the U.S. Federal Government are not required to transfer

copyright to the American Association for Cancer Research, Inc., since these articles are considered to be in the public domain. In the case of articles supported by federal grants or contracts, copyright transfer to the American Association for Cancer Research, Inc., is required. The federal government may retain a nonexclusive license to publish or republish such material.

The Journal will routinely allow authors (or others with the permission of the authors) to include select parts of a copyrighted article in reviews, books, or subsequent papers, upon written request to the AACR Director of Publications. Requests to reproduce an article in its entirety will be considered on an individual basis and permission may be granted contingent upon payment of an appropriate copyright fee. All reproduction requests must include a brief description of intended use and a stamped, self-addressed envelope. Third parties should obtain the approval of the authors *before* corresponding with the AACR.

Those who wish to photocopy articles should contact the AACR Publications Department [Telephone: (215) 440-9300; FAX: (215) 440-9355].

No responsibility is accepted by the Editors, by the American Association for Cancer Research, Inc., by the American Society of Preventive Oncology, or by Cadmus Journal Services for the opinions expressed by contributors or for the content of the advertisements.

Cancer Epidemiology, Biomarkers & Prevention is indexed in *Chemical Abstracts*, *Current Contents/CM*®, *Index Medicus*, *MEDLINE*, and the *BIOSIS Previews*® Database. This journal is printed on acid-free paper.

Cancer Epidemiology, Biomarkers & Prevention (ISSN 1055-9965) is published eight times annually in Jan/Feb, March, April/May, June, July/August, September, Oct/Nov, & December by the American Association for Cancer Research, Inc., Public Ledger Bldg., Suite 816, 150 South Independence Mall West, Philadelphia, PA 19106-3483 for \$50 annually for members, \$85 for individual nonmembers, and \$165 for institutional nonmembers. Second-class postage paid at Philadelphia, PA and additional mailing offices. POSTMASTER: Send address changes to *Cancer Epidemiology, Biomarkers & Prevention*, P. O. Box 3000, Denville, NJ 07834. Copyright 1995 by the American Association for Cancer Research, Inc. Printed in the U.S.A.

CD44v3 & CD44v6 Polyclonal Antibodies

For research in
breast, prostate, lung, colon, ovarian cancer
and other solid tumors.

CMB-CD44v3 \$289.00/100 µg vial
RABBIT ANTI-CD44v3 [CD44 Variant Isoform
with Exon -7 (v3)]

Form: This polyclonal rabbit anti-CD44v3 antibody is supplied at 1mg/ml in 10mM sodium phosphate, 150mM NaCl, 0.01% NaN₃, pH 7.5. The antibody is a serum form. Stable for 1 year at -20°.

Specificity: This polyclonal rabbit antibody to CD44v3 was produced using a synthetic peptide of human CD44v3 as immunogen. The antibody reacts specifically with human CD44v3 (≈200 kDa).

CMB-CD44v6 \$289.00/100 µg vial
RABBIT ANTI-CD44v6 [CD44 Variant Isoform
with Exon -10 (v6)]

Form: This polyclonal rabbit anti-CD44v6 antibody is supplied at 1mg/ml in 10mM sodium phosphate, 150mM NaCl, 0.01% NaN₃, pH 7.5. The antibody is a serum form. Stable for 1 year at -20°.

Specificity: This polyclonal rabbit antibody to CD44v6 was produced using a synthetic peptide of human CD44v6 as immunogen. The antibody reacts specifically with human CD44v6 (≈200 -250 kDa).

APPLICATION: Recent studies indicate that the expression of CD44 on the cell surface changes profoundly during tumor metastasis, particularly during the progression of various carcinomas. Sequencing analysis reveals that CD44 exists in different forms (at least 15 isoforms have been identified) that are variants of the common or standard hemopoietic form, CD44s. Specifically, the human CD44 gene contains 19 exons, out of which 10 exons can potentially be alternatively spliced. In particular, CD44s contains exons 1-5 and exons 15-19. The other exons (e.g. 6-14) are also spliced in a variety of different cells. For example, epithelial cells contain exons 12-14 inserted into the CD44s transcripts. This isoform has been designated as CD44E. Other CD44 variants (CD44v) have the same sequences at the two ends of the molecule, but differ in a middle region (with different numbers of additional exons) located on the external side of the cell membrane. It has been suggested that expression of CD44 variants with the additional exon 7/10 (so-called v3/v6) is responsible for tumor progression and metastasis. In fact, CD44v3/CD44v6 expression has been used as an indicator of metastasis.

USAGE: This antibody cross-reacts with human, rabbit, pig, mouse, rat, dog and bovine cells/tissues. It is used for research in breast, prostate, lung, colon, ovarian cancer and other solid tumors. It can be used for western blotting, ELISA, immunoprecipitation, immunofluorescence, flow cytometry and immunohistostaining of paraffin-embedded tissues. It can also be conjugated to numerous labels such as enzymes, fluorochromes, biotin or agarose.

REFERENCES:

Dall, P., K. H. Heider, A. Hekele, G. Minckwitz, M. Kaufmann, H. Ponta and P. Herrlich. *Cancer Res.* 54:3337-3341 (1994).

Screaton, G.R., M.V. Bell, D. G. Jackson, F. B. Cornelis, U. Gerth and J.I. Bell, *Proc. Natl. Acad. Sci. (USA)*, 89:12160-12164 (1992).

Arch, R., K. Wirth, M. Hofmann, H. Ponta, S. Matzku, P. Herrlich and M. Zoller. *Science* 257:682-685 (1992).

FOR RESEARCH PURPOSES ONLY. NOT FOR HUMAN OR DIAGNOSTIC USE.

TERMS AND CONDITIONS: F.O.B. WESTBURY, NY 2% 10 NET 30 DAYS

Prices subject to change without notice.

© Copyright 1995 Accurate Chemical & Scientific Corp.

ACCURATE Chemical & Scientific Corporation

300 SHAMES DRIVE, WESTBURY, NY 11590 USA • FAX: 1-516-997-4948

WESTBURY, NY: 516-333-2221 OR SAN DIEGO, CA: 619-296-9945

TOLL FREE: 1-800-645-6264 OR TOLL FREE: 1-800-255-9378

Assistant or Associate Professor/ Cancer Epidemiologist

Louisiana State University Medical Center-Shreveport
Center for Excellence in Cancer Research,
Treatment and Education

The Cancer Center at LSU Medical Center in Shreveport is currently recruiting for a chronic disease/cancer epidemiologist to work full-time in the Section of Cancer Control and Prevention.

The incumbent will participate in the design and implementation of cancer prevention programs, conduct (cancer) epidemiologic studies, and analyze and interpret epidemiologic data.

Requirements for the position are Ph.D. in Epidemiology, or M.D. with a MPH and sufficient post-doctoral training to be Board Eligible or Board Certified.

Interested candidates should submit an introductory letter with a description of research interests, a curriculum vitae, and a list of at least three references to Hans Berkel, M.D., Ph.D., Research Professor of Medicine, Chief, Section of Cancer Control and Prevention, LSU Medical Center - Shreveport, 1501 Kings Highway, Shreveport, LA 71133.

*LSU Medical Center is an Equal Opportunity
Educator and Employer*

Director, Transfer of Prevention Research



If you're looking for an organization where you can make the most of your talents and abilities, look to the American Cancer Society in Atlanta.

This Director position involves analyzing and monitoring cancer prevention research for possible applications as you track and provide periodic communication on emerging trends in cancer prevention.

Responsibilities include recommending prevention related research deemed ready for public application, providing periodic analysis of trends in prevention research, and recruiting volunteers with expertise in cancer risks and prevention to serve as an information resource on cancer causes, risks and prevention.

The successful candidate will have demonstrated analytic and conceptual skills and the ability to synthesize large amounts of information. Demonstrated skill in applying, communicating, and diffusing scientific research and solid proposal writing skills are required. Qualified candidates must have a Ph. D and 5-10 years experience in the conduct and application of biologic and/or behavioral research, preferably in cancer prevention. Demonstrated experience as a project manager and community applications of research are also required.

We offer a comprehensive benefits program, including generous vacation. Salary will be commensurate with ability and experience. For immediate consideration, please apply in strict confidence to: Human Resources, American Cancer Society, Inc., 1599 Clifton Rd., NE, Atlanta, GA 30329. E.O.E. M/F/D/V.

THE SURGERY BRANCH, NATIONAL CANCER INSTITUTE, NIH, IS SEEKING PATIENTS FOR ONGOING CLINICAL TREATMENT PROGRAMS.

PATIENTS WITH THE FOLLOWING MALIGNANCIES ARE BEING TREATED UNDER COMBINED MODALITY OR INNOVATIVE IMMUNOTHERAPY PROGRAMS:

- METASTATIC MELANOMA AND KIDNEY CANCER •
- STAGE II OR LOCALLY ADVANCED BREAST CANCER •
- METASTATIC COLORECTAL CANCER TO THE LIVER •
- LOCOREGIONAL GASTRIC OR PANCREATIC CANCER •
- MESOTHELIOMA, PULMONARY METASTASES, STAGE III A, B LUNG CANCER
OR ESOPHAGEAL CANCER •
- LOCALIZED SOFT TISSUE SARCOMAS •
- PERITONEAL CARCINOMATOSIS •

CARE FOR ALL PATIENTS IS PROVIDED AT THE CLINICAL CENTER, NIH, BETHESDA, MARYLAND.
FOR MORE INFORMATION ON CANCER PROGRAMS, PLEASE CALL (301) 496-1533.

**NATIONAL
CANCER
INSTITUTE**

A Public Service Announcement Courtesy of this Publication